|
 DEC.23, 2015
Anaeropharma Science released a
series of conference presentations in respect to
the new drug delivery system to produce Immune
Checkpoint Blockers inside hypoxic tumor.
Company Web
Site
NOV.25, 2015
JST assigns
Watervein as the promotor to a
new project developing Inhibitor Cystine
Knots(ICK) peptides by a novel phage display
technology for therapeutics targeting ion
channels by Dr. Tadashi Kimura, AIST. News Release(JST START
program)
NOV.19, 2015
Ipsen and
Interprotein enter
into a research collaboration and €165 million
option agreement for novel peptides in
endocrinology.
Release
SEP.15, 2014
MEXT assigns
Watervein as the promotor to
the project aiming therapeutic applications of
Adrenomedullin, a human peptide hormone, by
Dr. Kazuo Kitamura, Department of Internel
Medicine, Miyazaki University. News
Release(MEXT)
JUL.18,
2014
MEXT assigns
Watervein as the
promotor to the new type-2 diabetes drug
development by Dr. Kazuhito Tomizawa,
Department of Molecular Physiology, Kumamoto
University.
News
Release(MEXT)
JUL 10,
2014 The research findings of
Kinopharma's Nobel
Antiviral Drugs is published in "The
Journal of Clinical Investigation".
The Journal of Clinical
Investigation
OCT.10, 2013
MEXT assigns
Watervein
as the promotor to the new vector technology for
the next-generation cell reprograming being
invented by Dr. Mahito Nakanishi,
AIST. News
Release(MEXT)
APR.02,
2013 Anaeropharma
Science announces the initiation of a
phase 1 clinical trial of APS001F, a living
recombinant bifidobacterium to express the
cytosine deaminase gene, for patients with
advanced and/or metastatic solid tumors in
the United States.
News
Release
FEB.02, 2013 Drug
discovery deal between Interprotein
Corporation and RaQualia is
featured in the Top Story of BioCentury on
February 1, 2013.
BioCentury
FEB.20,
2012 Anaeropharma Science secures follow-on 2.2 billion
yen funding from INCJ.
News Release
DEC.27,
2011 Interprotein
Corporation enteres into an Agreeement
with Takeda Pharmaceutical in the field of Small
Molecule Inhibitors against Protein-protein
Interaction.
PharmaJapan
NOV.21,
2011 Ajinomoto Pharmaceuticals Co., Ltd.
and Interprotein Corporation Sign a Joint R&D and
Commercialization Agreement for Small Molecule
PPI (protein-protein
interaction) Inhibitors. This is the Second
Collaboration Tie-up between Two Companies.
Release
Sep.14, 2011 US NIH's
Recombinant DNA Advisory Committee make a
Recommendation for Ph.I/II study
of Anaeropharma Science Cancer Drug Candidate APS001F.
RAC
Meeting
AUG, 2011 A
Kinopharma's
Compound could be a Potent Anti-virus Drug
Candidate against Dengue Viruses for which
there is No Effective Cure, See
NEWS.
JUN.
2011 Interprotein has
outlined the company's Platform Drug Design
Technology called "INTENDD" in its
Web
Site.
APR.13,
2011 Interprotein is
Qualified as a Participant for "Space Open
Laboratory" at JAXA (the Japan Aerospace
Exploration Agency)
for its Small Molecule PPI
(protein-protein interaction) Inhibitor
Programs.
Japanese
Release
FEB.10,
2011
Carna
Biosciences, Inc. and KinoPharma,
Inc. Sign a Joint Research Agreement
for Drug Discovery for Neurodegenerative
Disorders.
NOV.01,
2010 Anaeropharma Science fundraises 700 million
yen - Capital Contribution by
Innovation Network Corporation of
Japan (INCJ).
OCT.01,
2010 Interprotein and
LegoChem Biosciences sign collaboration
agreement to develop VEGF inhibitor to treat
solid tumor
OCT.01,
2010 Eisai and Anaeropharma
Science Conclude Agreements Concerning
the Novel Anticancer Agent APS001 and a Drug
Delivery System Using Bifidobacterium Longum.
Release
SEP.27,
2010 Interprotein
Corporation and Ajinomoto
Pharmaceuticals Co., Ltd Sign
a Collaboration Agreement on Drug Discovery
Research.
| 
